First bacterial infection as an alternative clinical end point for regulatory approval of agents targeting the primary cystic fibrosis defect.
VanDevanter
Donald R
DR
Chiron Corporation Seattle, WA 98119, USA. Enigmaster@comcast.net
D001424:Bacterial Infections / Q000209:etiology*; D003550:Cystic Fibrosis / Q000150:complications* / Q000188:drug therapy*; D017277:Drug Approval; D006801:Humans; D017063:Outcome Assessment, Health Care / Q000379:methods*; D012141:Respiratory Tract Infections / Q000209:etiology*; D014481:United States